Pfizer announced its balance sheet for the fourth quarter of 2022.
In the statement, it was stated that the revenue of the company in the last quarter of last year increased by 2 percent compared to the same period of 2021 to $ 24.3 billion.
In the statement, it was stated that Pfizer’s revenue increased by 23 percent compared to the previous year in 2022 and reached 100.3 billion dollars, which is the highest revenue the company has achieved.
In the statement, it was stated that the 2023 revenues of the company are expected to decrease between 29 percent and 33 percent compared to last year, and it was noted that this year’s revenue estimation is between 67 billion dollars and 71 billion dollars.
In the statement, it was stated that the revenues of the Kovid-19 vaccine developed with BioNTech are expected to decrease by 64 percent to 13.5 billion dollars, and the revenues of Paxlovid antiviral drugs to 8 billion dollars with a decrease of 58 percent.